Kayvan Kamali, MD
Rheumatology · Longview, TXNPI 1013912856
Payments from drug & device makers
Across 1,533 payments — averaging $23.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$12K
- Amgen$7K
- Lilly USA, LLC$2K
- UCB, Inc.$2K
- GSK$2K
- Johnson & Johnson$1K
- plus $9K from 29 others
What the payments were for
- Food & beverage$35,205100%
- Education$1190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 495 | $12,032 |
| Amgen(2 entities) | 312 | $7,154 |
| Lilly USA, LLC | 80 | $2,023 |
| UCB, Inc. | 73 | $1,871 |
| GSK | 58 | $1,515 |
| Johnson & Johnson | 59 | $1,358 |
| AstraZeneca(2 entities) | 43 | $1,208 |
| Radius Health, Inc. | 73 | $1,191 |
| Novartis | 61 | $1,128 |
| Pfizer | 73 | $1,108 |
| Aurinia Pharma U.S., Inc. | 35 | $1,071 |
| Sanofi | 23 | $882 |
| E.r. Squibb & Sons, L.L.C. | 30 | $499 |
| Fresenius Kabi USA, LLC | 20 | $324 |
| Mallinckrodt Hospital Products Inc. | 10 | $312 |
| Collegium Pharmaceutical, Inc. | 12 | $225 |
| Boehringer Ingelheim | 12 | $220 |
| Bristol Myers Squibb | 11 | $192 |
| Genentech USA, Inc. | 10 | $153 |
| Eisai Inc. | 7 | $142 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Bioventus LLC | 4 | $103 |
| Organon | 7 | $86 |
| Sandoz | 4 | $72 |
| Biodelivery Sciences International, Inc. | 4 | $61 |
| ANI Pharmaceuticals, Inc. | 2 | $49 |
| Sanofi-aventis U.S. LLC | 3 | $44 |
| Daiichi Sankyo Inc. | 3 | $40 |
| Forte Bio-pharma LLC | 2 | $28 |
| Shield Therapeutics Inc | 1 | $25 |
| Assertio Therapeutics, Inc. | 1 | $19 |
| Pacira Therapeutics, Inc. | 1 | $17 |
| Mylan Institutional Inc. | 1 | $17 |
| Tonix Medicines, Inc. | 1 | $15 |
| Orthogenrx Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,324 in reported general payments places this provider in the 75th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 495 | $3,394,571 |
| RinvoqUpadacitinib | 167 | $1,074,507 |
| Enbrel SureclickEtanercept | 75 | $598,242 |
| Enbrel MiniEtanercept | 67 | $501,511 |
| Skyrizi PenRisankizumab-Rzaa | 20 | $422,031 |
| Cimzia (2 Pack)Certolizumab Pegol | 66 | $418,694 |
| Actemra ActpenTocilizumab | 82 | $355,751 |
| Xeljanz XrTofacitinib Citrate | 53 | $293,706 |
| Orencia ClickjectAbatacept | 46 | $272,949 |
| BenlystaBelimumab | 46 | $231,029 |
| Cosentyx Sensoready PenSecukinumab | 29 | $210,810 |
| ProliaDenosumab | 101 | $171,390 |
| KevzaraSarilumab | 22 | $101,184 |
| RemicadeInfliximab | 11 | $96,282 |
| EnbrelEtanercept | 11 | $94,216 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Savella | $12,032 | $1,097,304207 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,871 | $418,69466 claims |
| AmgenProlia, Enbrel, Otezla, Evenity (2 Syringes) | $7,154 | $364,657139 claims |
| GSKBenlysta | $1,515 | $231,02946 claims |
| SanofiKevzara | $882 | $101,18422 claims |
| Johnson & JohnsonRemicade | $1,358 | $96,28211 claims |
| Radius Health, Inc.Tymlos | $1,191 | $55,73821 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $225 | $14,75129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 512 rheumatology providers in Texas.
Other rheumatology in Longview
- Paul PickrellAustin$40.9M
- Atul SinghalMesquite$13.9M
- Shaikh AliTomball$9.8M
- Jitendra VasandaniLubbock$6.4M
- Dhiman BasuColleyville$6.2M
- Tamar BrionezThe Woodlands$5.2M
- Philip WallerHouston$4.9M
- John CushDallas$3.9M
- Sabeen NajamBaytown$3.6M
- Sanjay ChabraEl Paso$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.